Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI sponsored trials

Ítems similars

• Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
  per: Schroen, Anneke T, et al.
  Publicat: (2010)
• Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups
  per: Schroen, Anneke T., et al.
  Publicat: (2011)
• Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials
  per: Cheng, Steven K., et al.
  Publicat: (2011)
• Ongoing Use of Data and Specimens from NCI Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program
  per: Minasian, Lori, et al.
  Publicat: (2015)
• Economic Evaluations in NCI-sponsored Network Cancer Clinical Trials
  per: Nghiem, Van T., et al.
  Publicat: (2020)